Hybrigenics: Inecalcitol Advancing Towards Data
Edison | Jan 31, 2018 04:44AM ET
Hybrigenics’ (PA:ALHYG) main value driver is inecalcitol. A Phase II study in chronic myeloid leukaemia (CML) is on track to complete in H218. Interim analysis showed 33% of patients had a response after one year of treatment. A Phase II trial in acute myeloid leukaemia (AML) is ongoing with data expected in mid-2019. In another Phase II trial in chronic lymphocytic leukaemia (CLL), inecalcitol slowed progression in half of patients. In the field of inhibitors of ubiquitin-specific proteases (USP) the company has its own drug discovery programme and an R&D partnership with Servier focused on oncology worth up to €12m. Our valuation is broadly unchanged at €121m or €2.6/share.
Approaching key data in CML and AML
Inecalcitol continues its ongoing Phase II trial in CML with oral imatinib; the study is expected to be completed in H218. Interim data published in February 2017 showed that 33% of patients had a deep molecular response after one year of treatment, which we believe is encouraging. The Phase II study in AML in combination with decitabine has enrolled more than half of patients and will report results in mid-2019. In vitro data presented at the American Society of Haematology (ASH) meeting in December 2017 showed inecalcitol can induce the expression of CD38 in multiple myeloma cell lines, even more than other CD38 inducers, such as all-trans retinoic acid (ATRA), suggesting it could improve the efficacy of anti-CD38 products. We continue to forecast peak sales of $118.9m in AML and $257m in CML, in the US and the EU.
To read the entire report Please click on the pdf File Below:
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.